Skip to main content
Fig. 3 | Biomarker Research

Fig. 3

From: Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction

Fig. 3

Main blood-based biomarkers for ICI efficacy prediction. CTC, Circulating tumor cell; PD-L1, Programmed cell death-ligand 1; PD-1, Programmed cell death-1; TMR, Ratio of Tregs to Lox-1 + PMN- myeloid-derived suppressor cells; NLR, Neutrophil-to-lymphocyte ratio; LIPS, Signature of the liquid immune profile; TCR, T cell receptor; IL, Interleukin; CXCL, C-X-C motif chemokine ligand; LIF, Leukemia inhibitory factor; HIC, Host immune classifier; CRAFITY, CRP and AFP in immunotherapy; cfDNA, cell-free DNA; GIN, Genomic instability number; bTMB, Blood-based tumor mutation burden; MSI, Microsatellite instability; ctDNA, circulating tumor DNA; EV, Extracellular vesicle

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us